Prestige Raised Its Guide. The $2 Billion Debt Test Starts Now

Revenue and EPS improved, but debt still drives the thesis

One strong quarter does not settle the story.

Prestige delivered results investors wanted to see: Q1 revenue rose 6.5% to $265.7 million, adjusted diluted EPS reached $0.98, and management raised fiscal 2027 guidance to $1,290 million to $1,315 million of revenue and $4.55 to $4.65 of adjusted diluted EPS. Even so, the investment story remains centered on the balance sheet. At quarter-end, Prestige still carried roughly $2 billion of net debt, and it later added a $400 million senior notes offering. In other words, management extended the runway, but it did not eliminate the leverage.

That is why the debate persists. Bulls see more time to deleverage through cash generation as the company broadens beyond its legacy portfolio. Bears see a higher outlook that now depends more on acquired businesses, leaving less room for error. Either way, the key test is not revenue growth alone. It is whether Prestige can convert that growth into enough cash to start reducing balance-sheet pressure.

Organic growth shows the base business is improving

The quarter improved in a meaningful way.

The legacy portfolio was contributing more

Prestige reported organic sales growth of 3.2%, meaning the sales beat was not reliant on a single acquisition or a one-off boost. The reported growth excluded foreign-currency effects and a $5.9 million contribution from Breathe Right. That matters because acquired revenue can top-line a quarter; a healthier base business is harder to fake.

The main caveat is Clear Eyes. Management said variability in that brand remained a drag, so skeptics can reasonably argue that 3.2% organic growth is still early evidence rather than a fully clean signal of lasting portfolio strength. Even so, the company outperformed expectations organically despite that headwind, which suggests the legacy brands are not simply holding the line.

Acquired revenue helps the topline, but integration is the next test

Breathe Right also helped lift results. Management said the acquisition added about $6 million in quarterly revenue. The near-term math is straightforward, but the harder question is whether that acquired revenue scales without weakening the margins investors expect.

That is why cash conversion matters as much as brand headlines. The quarter included $70.8 million of cash from operating activities and adjusted free cash flow of $83.7 million. The important point going forward is not whether one quarter looked strong. It is whether Prestige can show that cash generation was not mostly a timing benefit and whether the combined business can support the raised outlook.

What has to happen next for the debt story to improve

From here, the raised outlook is a target to verify, not proof already earned. The near-term question is whether Prestige can show that adjusted free cash flow of $83.7 million was the start of a durable deleveraging path rather than a one-quarter flash.

The recent debt action matters because it changes the timing pressure. With the recent financing, the closest debt maturity moves to 2031, which takes the story away from immediate liquidity stress and puts it back on operating execution. The recent $400 million senior notes offering bought time; the next few quarters need to show that time is turning into a cleaner balance sheet.

What investors should watch next

• Whether organic growth holds up without depending on acquisition contribution
• Whether acquired revenue is integrating without margin dilution
• Whether free cash flow remains strong enough to support deleveraging
• Whether Clear Eyes variability stops limiting the progress seen in the legacy portfolio